Compare EHang Holdings Ltd - ADR (EH) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Organon & Co. Common Stock — how do they compare? EHang Holdings Ltd - ADR trades at $3.77 (market cap $289.73M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 12.5× EHang Holdings Ltd - ADR's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 47 Days and Organon & Co. Common Stock for 0 Days on average.
| EH | OGN | |
|---|---|---|
Market Cap | $289.73M | $3.62B |
Volume | 749,255 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $18.94 | $13.81 |
52-Week Low | $3.78 | $5.70 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $241.33M | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $3.78, down 4.79% on the day, reflecting a bearish technical trend. The company reported revenue of $418 million for 2025 but posted a net loss of $276 million, with negative profit margins and ROE. Recent news includes a law firm investigation into investor claims and expansion of its Global Fast Track Program to Vietnam. Cash flow from operations turned positive in 2024 at $158 million, but investing activities remain heavily negative due to capital expenditures.
The outlook is highly speculative, with significant execution and regulatory risks. Investment opportunity hinges on successful commercialization of eVTOL technology, but persistent losses and bearish analyst sentiment suggest caution. Key risks include ongoing legal scrutiny, intense competition, and reliance on future regulatory approvals for growth.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
